Details of the Drug-Related molecule(s) Interaction Atlas

Hypericum Drug Info

6-formamidopenicillanic acid; UNII-2TC14ZH3A5; CHEBI:59004; CTK2F8101; 6-formamido-2,2-dimethylpenam-3alpha-carboxylic acid; 2TC14ZH3A5; 64527-04-4; (2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-Formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; PAB 141; 141a/2A; HIS-1201; Epitope ID:119700; SCHEMBL11176911; DTXSID90429524; 6beta-formylaminopenicillanic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid, 6-(formylamino)-3,3-d

Cross-matching ID

PubChem CID

9548591

ChEBI ID

CHEBI:59004

CAS Number

CAS 64527-04-4

TTD Drug ID

DM8NWFD

VARIDT Drug ID

DR01095

General Information of Drug (ID: DM8NWFD)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[3]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[4]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[5]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[6]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[7]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[6]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[8]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
2	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
3	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
4	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
5	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
6	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
7	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
8	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
9	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.